The Effect of Aging on LAIV Replication in Human Nasal Epithelial Cells

衰老对人鼻上皮细胞 LAIV 复制的影响

基本信息

  • 批准号:
    8719907
  • 负责人:
  • 金额:
    $ 7.6万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-08-15 至 2016-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The increased susceptibility to seasonal influenza coupled with decreased vaccine efficacy among older adults, who make up the fastest growing population in the United States, constitutes an emerging public health crisis. The Live Attenuated Influenza Vaccine (LAIV) is a nasally administered vaccine that has been shown to be more effective than the trivalent inactivated vaccine (TIV) in pediatric populations due to its ability to replicate and elicit a mucosal immune response at the site of natural infection - the nasal epithelium. Our preliminary data demonstrate that the LAIV exhibits significantly less replication in human nasal epithelial cell (hNEC) cultures from adults over 65 compared with younger subjects. Inadequate infection of the nasal epithelium limits the vaccine-activated immune response and we hypothesize that decreased LAIV infection and replication in the nasal epithelium of older adults contributes to the reduced vaccination efficacy. This proposal aims to characterize the defect in LAIV infection of nasal epithelial cells from older adults by comparing virus replication and nasal epithelial cell immune responses between adults over 65 and younger subjects between the ages of 5 and 17. The functional significance of any differences in the epithelial cell-derived immune responses between younger and older hosts will be assessed in order to identify potential mechanisms at the level of the epithelium, which modulate immune responses to the LAIV. Then we will study the effect of aging on the interaction between hNECs and dendritic cells in order to gain insight into how these age-specific changes in LAIV replication and nasal epithelial immune responses affect the dendritic cell-initiated adaptive immune response. The ultimate goal of this project is to identify age-specific epithelial cell factors that affect virus replication, which can then be used in the development of either novel vaccines with expanded immunoprotection or immune-modulatory adjuvants that can improve vaccine efficacy in older adults by enhancing vaccine replication.
描述(由申请方提供):老年人对季节性流感的易感性增加,加上疫苗效力降低,构成了美国增长最快的人口,构成了一场新的公共卫生危机。减毒流感活疫苗(LAIV)是一种经鼻接种的疫苗,由于其在自然感染部位(鼻上皮)复制和引发粘膜免疫应答的能力,已被证明在儿科人群中比三价灭活疫苗(TIV)更有效。我们的初步数据表明,LAIV在65岁以上成人的人鼻上皮细胞(hNEC)培养物中的复制显著低于年轻受试者。鼻上皮的感染不足限制了疫苗激活的免疫应答,我们假设老年人鼻上皮中LAIV感染和复制的减少有助于降低疫苗接种效果。该提案旨在通过比较65岁以上成年人和5至17岁年轻受试者之间的病毒复制和鼻上皮细胞免疫应答来表征老年人鼻上皮细胞LAIV感染的缺陷。将评估年轻和老年宿主之间上皮细胞源性免疫应答的任何差异的功能意义,以确定调节对LAIV的免疫应答的上皮水平的潜在机制。然后,我们将研究衰老对hNECs和树突状细胞之间相互作用的影响,以深入了解LAIV复制和鼻上皮免疫应答中的这些年龄特异性变化如何影响树突状细胞启动的适应性免疫应答。该项目的最终目标是确定影响病毒复制的年龄特异性上皮细胞因子,然后可用于开发具有扩大免疫保护的新型疫苗或免疫调节佐剂,通过增强疫苗复制来提高老年人的疫苗效力。

项目成果

期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Ebola virus disease: What clinicians in the United States need to know.
Global burden of influenza as a cause of cardiopulmonary morbidity and mortality.
  • DOI:
    10.1016/j.gheart.2014.08.004
  • 发表时间:
    2014-09
  • 期刊:
  • 影响因子:
    3.7
  • 作者:
    Fischer, William A 2nd;Gong, Michelle;Bhagwanjee, Satish;Sevransky, Jonathan
  • 通讯作者:
    Sevransky, Jonathan
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

William Fischer其他文献

William Fischer的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('William Fischer', 18)}}的其他基金

The Protective and Pathologic Features of the EVD Survivor Immune System
埃博拉病毒病幸存者免疫系统的保护和病理特征
  • 批准号:
    10639583
  • 财政年份:
    2023
  • 资助金额:
    $ 7.6万
  • 项目类别:
Prevalence, Pathogenesis, and Persistence of Lassa Fever in West Africa
西非拉沙热的流行情况、发病机制和持续性
  • 批准号:
    10362526
  • 财政年份:
    2018
  • 资助金额:
    $ 7.6万
  • 项目类别:
Prevalence, Pathogenesis, and Persistence of Lassa Fever in West Africa
西非拉沙热的流行情况、发病机制和持续性
  • 批准号:
    10092912
  • 财政年份:
    2018
  • 资助金额:
    $ 7.6万
  • 项目类别:
Clinical Sequelae and Urogenital Viral Dynamics in Survivors of Ebola Virus Disease
埃博拉病毒病幸存者的临床后遗症和泌尿生殖系统病毒动态
  • 批准号:
    9311358
  • 财政年份:
    2017
  • 资助金额:
    $ 7.6万
  • 项目类别:
Clinical Sequelae and Urogenital Viral Dynamics in Survivors of Ebola Virus Disease
埃博拉病毒病幸存者的临床后遗症和泌尿生殖系统病毒动态
  • 批准号:
    9014070
  • 财政年份:
    2016
  • 资助金额:
    $ 7.6万
  • 项目类别:
The Effect of Aging on LAIV Replication in Human Nasal Epithelial Cells
衰老对人鼻上皮细胞 LAIV 复制的影响
  • 批准号:
    8556553
  • 财政年份:
    2013
  • 资助金额:
    $ 7.6万
  • 项目类别:

相似海外基金

Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
  • 批准号:
    23K08213
  • 财政年份:
    2023
  • 资助金额:
    $ 7.6万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
  • 批准号:
    2881726
  • 财政年份:
    2023
  • 资助金额:
    $ 7.6万
  • 项目类别:
    Studentship
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
  • 批准号:
    10722146
  • 财政年份:
    2023
  • 资助金额:
    $ 7.6万
  • 项目类别:
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
  • 批准号:
    10735090
  • 财政年份:
    2023
  • 资助金额:
    $ 7.6万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 7.6万
  • 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
  • 批准号:
    10935776
  • 财政年份:
    2023
  • 资助金额:
    $ 7.6万
  • 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
  • 批准号:
    10935796
  • 财政年份:
    2023
  • 资助金额:
    $ 7.6万
  • 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
  • 批准号:
    10935775
  • 财政年份:
    2023
  • 资助金额:
    $ 7.6万
  • 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
  • 批准号:
    10649041
  • 财政年份:
    2023
  • 资助金额:
    $ 7.6万
  • 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
  • 批准号:
    10735964
  • 财政年份:
    2023
  • 资助金额:
    $ 7.6万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了